CN102861078A - Application of Houttuynoid D in medicine for treating prostatic cancer - Google Patents
Application of Houttuynoid D in medicine for treating prostatic cancer Download PDFInfo
- Publication number
- CN102861078A CN102861078A CN2012104186405A CN201210418640A CN102861078A CN 102861078 A CN102861078 A CN 102861078A CN 2012104186405 A CN2012104186405 A CN 2012104186405A CN 201210418640 A CN201210418640 A CN 201210418640A CN 102861078 A CN102861078 A CN 102861078A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- medicine
- prostatic cancer
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
The invention discloses application of Houttuynoid D in preparation of a medicine for treating prostatic cancer, belonging to the technical field of new application of medicine. The invention discovers that Houttuynoid D has the remarkable inhibitory effects on the growth of human prostatic cancer cell strains, including ALVA, gpc-1, 9L-B and Du145 through the evaluation of in-vitro MTT antineoplastic activity. Therefore, Houttuynoid D can be used for preparing the anti-prostatic cancer medicine and has good development and application prospects. The application of Houttuynoid D in preparation of the medicine for treating prostatic cancer provided by the invention is disclosed firstly. The skeleton type belongs to new skeleton type, and the inhibitory activity of Houttuynoid D on prostatic cancer cells is unexpectedly strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid D, relate in particular to the application of Houttuynoid D in the preparation antiprostate cancer.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid D that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid D that the present invention relates in preparation treatment carcinoma of prostate medicine, because framework types belongs to brand-new framework types, and its inhibition for prostate gland cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously carcinoma of prostate obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid D in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid D in the preparation antiprostate cancer, and the structural formula of Houttuynoid D is shown in formula I:
The present invention finds that by external MTT anti-tumor activity evaluation Houttuynoid D also has significant inhibitory action to the growth of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145, suppresses the IC of this 4 strain Growth of Cells
50Value is respectively 0.19 ± 0.03 μ M, 0.16 ± 0.06 μ M, 1.13 ± 0.15 μ M and 2.14 ± 0.36 μ M.Therefore, Houttuynoid D can for the preparation of antiprostate cancer, have good development prospect.
The purposes of the Houttuynoid D that the present invention relates in preparation treatment carcinoma of prostate medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for prostate gland cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously carcinoma of prostate obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid D involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid D tablet involved in the present invention:
Get 20 and digest compound Houttuynoid D, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid D capsule involved in the present invention:
Get 20 and digest compound Houttuynoid D, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid D to the growth inhibited effect of human prostate cancer cell line
1. method: the cell that is in the growth logarithmic (log) phase: human prostate cancer cell line ALVA, gpc-1,9L-B and Du145(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid D of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid D has significant inhibitory action to the growth of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145.This chemical compound suppresses the IC of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145 growth
50Value is respectively: 0.19 ± 0.03 μ M, 0.16 ± 0.06 μ M, 1.13 ± 0.15 μ M and 2.14 ± 0.36 μ M.
Shown that by above-described embodiment Houttuynoid D of the present invention has good inhibitory action to the growth of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145.Prove that thus Houttuynoid D of the present invention has the anti-prostate cancer activity, can be for the preparation of antiprostate cancer.
Claims (1)
1.Houttuynoid the application of D in treatment carcinoma of prostate medicine, described compound H outtuynoid D structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418640.5A CN102861078B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in medicine for treating prostatic cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418640.5A CN102861078B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in medicine for treating prostatic cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102861078A true CN102861078A (en) | 2013-01-09 |
| CN102861078B CN102861078B (en) | 2014-04-16 |
Family
ID=47440396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210418640.5A Active CN102861078B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in medicine for treating prostatic cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861078B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1880328A (en) * | 2006-04-30 | 2006-12-20 | 重庆大学 | Preparation method of hyperin and hypericin of Hypericum perforatum |
| CN102697942A (en) * | 2012-01-04 | 2012-10-03 | 陈玉堂 | Medicament capable of killing cancer cells and curing various tumors and cancers and leukemia |
-
2012
- 2012-10-27 CN CN201210418640.5A patent/CN102861078B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1880328A (en) * | 2006-04-30 | 2006-12-20 | 重庆大学 | Preparation method of hyperin and hypericin of Hypericum perforatum |
| CN102697942A (en) * | 2012-01-04 | 2012-10-03 | 陈玉堂 | Medicament capable of killing cancer cells and curing various tumors and cancers and leukemia |
Non-Patent Citations (2)
| Title |
|---|
| SHAO-DAN CHEN ET AL: "Houttuynoids A-E, anti-herpes simplex virus active flavonoids with novel skeletons from houttuynia cordata", 《ORGANIC LETTERS》 * |
| 李爽 等: "鱼腥草的有效成分、药理作用及临床应用的研究进展", 《沈阳药科大学学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102861078B (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102861078B (en) | Application of Houttuynoid D in medicine for treating prostatic cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102861084B (en) | Application of Houttuynoid D in medicine for treating ileocecum cancer | |
| CN102872150B (en) | Application of Houttuynoid B in medicament for treating prostatic cancer | |
| CN102872095B (en) | Application of Houttuynoid E in medicine for treating ileocecum cancer | |
| CN102861097B (en) | Application of Houttuynoid E in medicine for treating bladder cancer | |
| CN102861073A (en) | Application of Houttuynoid A in medicine for treating colorectal cancer | |
| CN102872101B (en) | Application of Houttuynoid C in medicine for treating ileocecum cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102861093B (en) | Application of Houttuynoid B in medicine for treating colorectal cancer | |
| CN102861071B (en) | Application of Houttuynoid A in medicine for treating gastric cancer | |
| CN102861065A (en) | Application of Houttuynoid E in medicine for treating gastric cancer | |
| CN102861070B (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102895249A (en) | Application of Houttuynoid E to medicament for treating prostatic carcinoma | |
| CN102861080A (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102872103A (en) | Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma | |
| CN102861074A (en) | Application of Houttuynoid B in medicine for treating bladder cancer | |
| CN102872070A (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102861069A (en) | Application of Houttuynoid B in medicine for treating laryngocarcinoma | |
| CN102861064A (en) | Application of Houttuynoid E in medicine for treating laryngocarcinoma | |
| CN102861086A (en) | Application of Houttuynoid E in medicine for treating ovarian cancer | |
| CN102861048A (en) | Application of Houttuynoid A in medicine for treating nasopharyngeal carcinoma | |
| CN102861075A (en) | Application of Houttuynoid B in medicine for treating gastric cancer | |
| CN102861077A (en) | Application of Houttuynoid D in medicine for treating cervical cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QIDONG TIANFEN ELECTRIC TOOL TECHNOLOGY INNOVATION Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141128 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226241 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141128 Address after: Qidong City, Jiangsu province 226241 Nantong lvsigang Tianfen electric tools trade city comprehensive building Patentee after: Qidong Tianfen Electric Tool Technology Innovation Center Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |